Results of 4 trials involving bisphosphonates in a range of protocols and patient cohorts suggest that the role of these agents in preventing recurrence of breast cancer remains to be defined. In 2 of the 4 studies reported, favorable outcomes were obtained following intravenous administration of zoledronic acid. Neither of two trials in which a bisphosphonate was administered orally, however, achieved its primary endpoint.
Bevacizumab (Avastin) improved progression-free survival (PFS) in women with HER2-positive locally recurrent or metastatic breast cancer by an average of 3 months when added to standard treatment as first-line therapy in the multinational, randomized, phase III AVEREL study.
Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in progression-free survival (PFS) in women with metastatic breast cancer when the immunosuppressant agent is combined with the hormonal therapy exemestane.
Although some preventive steps can now be taken by women to reduce environmental factors that contribute to breast cancer risk, much more research is needed to clarify the role of recognized and suspected environmental factors, according to a new report issued by the Institute of Medicine.
SABCS: Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer
Addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to a 38% reduction in risk of disease worsening or death in patients with HER2-positive metastatic breast cancer, reported investigators from the randomized, double-blind, placebo-controlled phase III CLEOPATRA study.
At this year’s San Antonio Breast Cancer Symposium, new data results from four different clinical trials of bisphosphonate usage in patients with breast cancer will be presented and discussed.
The San Antonio Breast Cancer Symposium brings together basic science researchers and clinicians for the latest breast cancer research-related progress. The symposium has evolved from a 1-day local conference to a 5-day international meeting focusing on clinical, preventive, diagnostic, translational, and basic research.
Cancer Network interviews Kent Osborne, who is the moderator of the year in review session. He has been involved with the meeting since its beginning. The international San Antonio Breast Cancer Symposium is unique as it facilitates the interaction of both basic and science researchers and clinicians to combine the efforts of laboratory research and clinical research for better treatment and patient care.